Chris Polman, Free University of Amsterdam
Abstract N Engl J Med 2006;345:899
Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
[audio:https://www.audiomedica.com/podcasting/news/chris_polman.mp3]
MRSA: Fight Superbug Using Hydrogen Peroxide Vapour 18 Sep, 2007 DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates 21 Sep, 2007 Nosocomial Clostridrium Difficile: Reduce by Cleaning with Household Bleach 19 Sep, 2007 Best Evidence Yet that Folic Acid Fortification Reduces Neural-Tube Defects 2 Aug, 2007 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014